![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-desktop-w27gif-57924.gif)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-mobile-w27gif-62411.gif)
Active Filter(s):
Details:
Under the agreement, Ardena will provide additional Good Manufacturing Practice (cGMP)-standard manufacturing capability for Race’s flagship intravenous (IV) formulation of RC220 (bisantrene dihydrochloride).
Lead Product(s): Bisantrene
Therapeutic Area: Oncology Product Name: RC220
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Race Oncology
Deal Size: $1.0 million Upfront Cash: Undisclosed
Deal Type: Agreement July 12, 2023